A b s t r a c t
Transfusion-related acute lung injury (TRALI) is the number one cause of transfusion-related fatalities reported to the Food and Drug Administration. 1 TRALI is defined as new acute lung injury that occurs during or within 6 hours after transfusion, as indicated by the presence of hypoxemia (PaO 2 /fraction of inspired oxygen ratio of ≤300 mm Hg or oxygen saturation of ≤90% while breathing room air) and bilateral infiltrates seen on frontal chest radiograph, in the absence of circulatory overload. 2, 3 Hypertension or hypotension, fever, and acute transient leukopenia are other findings observed in TRALI. 4 The condition of patients in whom TRALI develops typically improves within 48 to 96 hours of onset, and patients recover without permanent sequelae. 4 However, mortality rates of 5% to 25% have been reported. 4, 5 The true incidence remains unknown because clinicians may not recognize TRALI when it occurs; therefore, it is likely underreported to hospital blood banks and blood centers. The incidence in the United States has been estimated to range from 1:1,120 to 1:5,000 transfused units. 4, 6 The cause of this uncommon syndrome is unclear, but 2 hypotheses have been proposed. The immune-mediated hypothesis proposes a role for HLA class I, class II, and granulocyte antibodies, often found in multiparous female blood donors, in the pathogenesis of TRALI. 4, 7 It is hypothesized that transfusion of these antibodies into a recipient who has the cognate antigens leads to neutrophil activation and release of oxidative substances that damage the pulmonary endothelium. Fewer than 10% of TRALI cases involve the reverse mechanism in which the recipient has HLA or granulocyte antibodies that match residual donor WBC antigens. 4 The only diagnostic test available for TRALI is identification of HLA and granulocyte antibodies in donor and/or recipient plasma. The finding of antigen-antibody concordance strongly supports the diagnosis of TRALI.
In 15% of TRALI cases, no antigen-antibody concordance is found; therefore, a second hypothesis has been advanced, proposing that 2 distinct events are necessary for TRALI to occur. The first is related to the recipient's clinical condition (eg, active infection or recent surgery), and the second is the infusion of blood product(s) containing HLA and/or granulocyte antibodies or other biologic response modifiers, such as cytokines, lipids, and platelet-derived soluble CD40 ligand. 8, 9 Currently, evaluation of biologic response modifiers is not used for diagnostic testing of TRALI. However, their presence in cellular blood products may be a critical factor in the pathogenesis of non-antibody-mediated TRALI.
One means of determining the processes that lead to TRALI would be to determine the risk factors associated with the disease. It is usually challenging to identify risk factors and potential causes of diseases that occur infrequently, and case-control studies are often required to delineate the critical factors that are causally related. However, only 1 TRALI casecontrol study has been reported. 6 Because of the dearth of such studies, this project was conducted to provide preliminary assessment of recipient, donor, and blood component characteristics that may be risk factors associated with the development of TRALI.
Materials and Methods

Case and Control Selection
The institutional review board of the University of California San Francisco approved the study. A retrospective review of all transfusion reactions reported to and investigated by the university blood bank from January 2002 through September 2004 identified 5 cases that had received the final diagnosis of TRALI. All cases had donor HLA antibody that matched recipient antigen.
Based on the incidence of TRALI reported by others, we had projected that 5 additional cases of TRALI would be enrolled during the study period, October 2004 through October 2005. A case-control ratio of 1:2 had been targeted for a total of 10 cases and 20 control subjects. However, only 1 additional TRALI case was reported; therefore, 6 cases and 20 control subjects were studied.
All 6 cases reported to the blood bank were highly probable cases of TRALI, based on acute onset of hypoxemia and bilateral chest infiltrates after transfusion. Fluid overload was excluded in each case. Case 1 was a nonsurgical patient who had normal fluid balance and no history of heart disease. An echocardiogram performed at the time of the transfusion reaction showed no indication of cardiac failure. Case 2 was a medical patient undergoing continuous venovenous hemofiltration with a negative fluid balance. Case 3 was a surgical patient who had no clinical indication of cardiac decompensation intraoperatively, but copious frothy secretions developed in the endotracheal tube and increased ventilator support was required. Case 4 was a surgical patient in whom copious frothy secretions developed in the endotracheal tube postoperatively. The pulmonary edema/serum protein ratio was 0.8, indicative of noncardiogenic pulmonary edema. Case 5 was a medical patient undergoing continuous venovenous hemofiltration with a negative fluid balance. Case 6 was a surgical patient in whom transient leukopenia, fever, and acute dyspnea developed postoperatively. An echocardiogram revealed a normal ejection fraction, suggesting a noncardiogenic cause for the pulmonary edema.
All cases reviewed met the Canadian consensus panel and the National Heart, Lung, and Blood Institute working group definitions for TRALI. 2, 3 As part of the TRALI investigation, donors who were most likely implicated in the TRALI reactions were tested for HLA class I, class II, and granulocyte antibodies. The HLA type was determined for each patient with TRALI. One of the patients with TRALI (case 4) was a 13-year-old girl who had received whole blood units from her mother and 2 maternal aunts. Transfusions from first-degree family members confer a significant risk of TRALI owing to the likelihood of HLA-antibody concordance. 10, 11 The analysis was carried out twice, with and without inclusion of case 4, to ensure that our findings were not dominated by this single case.
Because the number of blood products transfused into patients with TRALI varied substantially, we used stratified logistic regression analysis to compare cases with control subjects. The patients with TRALI were assigned to 3 strata or transfusion levels: low (1-2 U), medium (3-9 U), and high (≥10 U). Only the number of units was considered, regardless of the type of blood product.
Potential control subjects were identified based on the same transfusion strata, using a list of randomly determined calendar dates from October through December 2004. Subjects who had received the targeted level of transfusions were identified from a daily blood bank report that listed all patients receiving transfusions and the number of blood products received per patient within a 24-hour period. A ratio of 4:2:14 (low/medium/high transfusion strata) was defined for selection of the 20 control subjects. Other variables characterizing cases and control subjects were left unmatched so that the variables could be studied as risk factors for TRALI. Control subjects were defined as recipients who did not experience a transfusion reaction, as judged by the fact that no transfusion reaction report was received by the blood bank. In addition, the medical record was reviewed to confirm that no signs or symptoms of TRALI had been recorded during or after transfusion. If a chest radiograph had been recorded during or after transfusion for other clinical purpose, it was reviewed to confirm the absence of bilateral infiltrates or pulmonary edema. If no chest radiograph was available, we assumed the subject had not had severe enough respiratory symptoms to warrant one. If a CBC count was available following 1 hour after transfusion, it was reviewed for the presence or absence of transient leukopenia, which may be observed in TRALI. 12 
Risk Factors Studied
Recipient age, sex, diagnosis, underlying infection or autoimmune disease, and recent history of surgery were risk factors studied. Information about the donors of blood received by the control subjects and patients with TRALI was also collected. Blood donor and product characteristics evaluated included donor age and sex, storage time, and type of blood product: whole blood vs components and leukocytereduced vs non-leukocyte-reduced. To evaluate the risk of female donor plasma, the amount of female donor plasma per unit transfused was approximated by using standard estimates of residual plasma present in various blood components.
Statistical Analysis
The volume of blood product received by the patients in whom TRALI developed covered a wide range. To identify recipient and blood component characteristics other than volume, which appeared to be predictive for TRALI, stratified logistic regression was used. The patients were categorized as belonging to the low, medium, or high stratum depending on transfusion volume, and control subjects were selected corresponding to the same strata. Results of the analysis are reported as odds ratios (ORs).
Because of the small number of cases, we focused mainly on models containing a single predictor, and we used exact methods 13 to avoid approximations that may be invalid with small numbers. The effect of receiving any units vs no units of cryoprecipitate, fresh frozen plasma, platelets, RBCs, or whole blood was analyzed. The total number of units of each component type was also evaluated.
Results
Recipient Risk Factors
Recipient demographics and clinical conditions are summarized in ❚Table 1❚, and their estimated associations with the risk of TRALI are shown in ❚Table 2❚. The strongest association was with spinal surgery, yielding an infinite OR when controlled for transfusion stratum in a matched analysis. A hematologic-oncologic clinical diagnosis in a recipient had the most negative association with TRALI.
Blood Product and Donor Risk Factors
The number of whole blood units transfused was the only factor related to donor or blood product that emerged as a clear predictor for TRALI. Table 2 shows the univariate ORs for all potential predictors of TRALI studied. When a logarithmic scale was used in the analysis, the number of whole blood units remained statistically significant with a similar P value (OR, 5.37 per 2-fold increase in number of units; P = .014). Given this result, the number of whole blood units and number of designated-donor whole blood units were analyzed as 2 linear predictors; because it was not possible to use exact methods, stratified, nonexact logistic regression was used. The risk of TRALI from designated-donor whole blood units did not seem to be higher in comparison with random donor whole blood units (OR estimated to be greater for designateddonor units than for other whole blood by a factor of only 1.13; 95% confidence interval [CI], 0.09-14.1; P = .93), but the extremely wide CI precludes any firm conclusion.
Of the 3 patients with TRALI who received whole blood, 2 received a combination of allogeneic and autologous whole blood units. The other received only autologous blood. Of the 4 control subjects who received whole blood, 2 received only allogeneic whole blood units, 1 autologous, and 1 a combination of both types. Thus, among TRALI cases, transfusion of allogeneic whole blood units was not predominant.
Although the number of leukocyte-reduced units transfused appeared to be protective against TRALI in a univariate analysis ( Table 2 ), this finding disappeared completely when we controlled for number of whole blood units in a 2-predictor model (OR, 1.05; 95% CI, 0.78-1.41; P = .65). The 3 patients with TRALI who received whole blood units also underwent spinal surgery. The sparseness and configuration of the data did not permit estimation of effect of spinal surgery controlled for number of whole blood units, so we could not determine whether one of these factors might explain the apparent effect of the other. Although estimates for other potential predictors of TRALI did not reach statistical significance, we noted that CIs often included values large enough to constitute clinically significant risk and sometimes overlapped the CI for whole blood. Thus, conclusions about lack of risk of other predictors or whether whole blood is substantially more risky than other components are not strongly supported by this small study.
In the 6 TRALI cases reviewed, tests had been conducted for the presence of relevant HLA and granulocyte antibodies in donor plasma most closely implicated in the onset of TRALI symptoms. Leukocyte antibody testing was limited to the TRALI cases because in control subjects, donor plasma was not available. There was concordance between the recipient's HLA and donor antibody in all 6 cases tested ❚Table 3❚. Implicated donor samples were tested for granulocyte antibodies. Donors for TRALI cases 1 and 6 were negative, donors for cases 2 and 3 were not tested, and donors for cases 4 and 5 were positive, but no specificity was identified.
Discussion
A pilot case-control study has indicated that the number of whole blood units transfused was a primary predictor for TRALI (OR, 3.0 per unit; P = .0098). Not all whole blood units transfused to patients with TRALI were tested for leukocyte antibodies because they were from autologous collections, not available, or not transfused within 6 hours of the transfusion reaction. Autologous whole blood units would not be expected to contain leukocyte antibodies. In the Mayo Clinic (Rochester, MN) series, leukocyte antibodies were identified in whole blood, RBCs, and fresh frozen plasma in 21, 10, and 5 cases, respectively. 4 In this series, in 21 of 36 cases, leukocyte antibody was found in whole blood units associated with TRALI. 4 HLA and granulocyte antibodies of undetermined specificity were identified in the serum of at least 1 implicated donor in 89% (32/36) of the cases. 4 This observation has provided a basis for the proposed immunemediated mechanism for TRALI. FFP, fresh frozen plasma; SDP, single donor plateletpheresis; WB, whole blood. * Implicated products were transfused during or within 6 hours of the transfusion reaction, and all donors but 1 (unknown parity) were multiparous females.
† HLA antibody that is concordant to the recipient HLA(s). Although whole blood was the only statistically significant risk factor, it was somewhat surprising that female donors and previously implicated blood product types, fresh frozen plasma and plateletpheresis, which are more likely to contain HLA antibodies, did not seem to be risk factors for TRALI. This suggests that a simple antibody-antigen reaction may not provide a sufficient mechanism for the occurrence of TRALI. Others have proposed a 2-event mechanism that could explain our observations. According to the 2-event hypothesis of TRALI, biologic response modifiers (eg, lipids, cytokines, platelet-derived soluble CD40 ligand, 9 or leukocyte antibodies) in older or non-leukocyte-reduced blood components prime neutrophils in transfusion recipients. The primed neutrophils can then produce lung injury and the symptoms associated with TRALI if the recipient has a predisposing clinical condition. The fact that blood components from one donor may cause TRALI in some recipients and not others supports such a mechanism that includes antibody-independent routes and factors associated with the recipient's clinical condition. 14, 15 Half of the TRALI cases in this study received non-leukocyte-reduced whole blood units ranging in storage time from 4 to 28 days. However, whole blood was given within 6 hours of the reaction in only 1 TRALI case. In the other cases, the whole blood units were transfused more than 6 hours before the reaction and, therefore, would not be considered to be implicated according to the new definition of TRALI. 2, 3 All 6 cases described in this study have HLA-antibody concordance associated with TRALI. This is a welldescribed hypothesis for the pathogenesis of TRALI, but antigen-antibody concordance does not necessarily result in clinical TRALI. In a look-back study, Toy et al 14 investigated a multiparous female donor who had multiple HLA antibodies that were reactive with 96% of HLA class I antigens and 88% of HLA class II antigens. None of a subset of 55 nonneutropenic patients with known HLA types developed TRALI after transfusion of blood products from the donor, even though 98% had 1 to 5 corresponding HLAs. In some cases of antigen-antibody concordance, other biologic response modifiers may be required for the development of TRALI, eg, in the 3 cases in our study in which whole blood was transfused before or together with the donor antibody, cytokines or other biologic response modifiers in non-leukocyte-reduced whole blood could be the other factor required for the development of TRALI.
In our study, the number of whole blood units transfused was the only factor that emerged as a clear predictor for TRALI. This finding is not directly predicted from the current hypotheses of mechanisms for TRALI. The antigen-antibody hypothesis would predict that all plasma-containing blood products, not just whole blood, would be a risk factor. The 2-event hypothesis would predict that products with risk are those that contain biologic response modifiers, such as non-leukocyte-reduced products that are known to contain more leukocyte cytokines. This study was too small to rule out these possibilities or to permit further investigation using multivariate analyses.
A possible explanation is that unmodified whole blood contains platelets, because platelet-rich plasma is not removed during preparation of whole blood. Thus, unmodified whole blood may contain nonviable platelets and platelet-derived cytokines. Indeed, Khan et al 9 showed that platelet-derived soluble CD40 ligand promotes neutrophil-mediated cytotoxicity of human pulmonary microvascular endothelial cells as the second event in the 2-event in vitro model of TRALI. Furthermore, platelets have a role in the development of acute lung injury. By using a murine model of acid-induced acute lung injury, Zarbock et al 16 showed that platelet-neutrophil interactions are critical to the development of acute lung injury. Thus, nonviable platelets and platelet-derived mediators are a plausible mechanism to potentially explain the observed risk of unmodified whole blood for TRALI.
In the only previously reported nested case-control study, which involved 46 TRALI cases and 225 control subjects, Silliman et al 6 noted that the platelet age of TRALI cases compared with that in controls was a statistically significant risk factor. The implicated units were stored for a mean ± SD of 4.5 ± 0.2 days, vs 4.2 ± 0.1 days for control units. 6 The platelet concentrates were not leukocyte-reduced and, thus, could have primed recipient neutrophils, in contrast with our study, in which platelet units transfused were from single-donor apheresis and leukocyte-reduced. Recently, soluble CD40 ligand has been shown to accumulate during platelet storage. It has the ability to prime neutrophils that express CD40, causing endothelial damage and possibly TRALI in predisposed patients. 9 Although the mean and maximum storage times of cellular components did not seem to increase risk of TRALI in this study (Table 2) , the upper confidence bounds were large enough to be consistent with a role of soluble CD40 in TRALI.
One can postulate that the biologic response modifiers in whole blood and the recipient's underlying clinical condition were the first event that resulted in priming of the neutrophils, and the second event was the presence of HLA or granulocyte antibodies in other implicated transfused units. In patients with TRALI who did not receive whole blood units, we surmise that factors arising from their clinical conditions may have primed the neutrophils and that transfusion of an HLA antibody against a cognate antigen then triggered the TRALI reaction.
Silliman et al 6 identified 2 groups of patients as being at risk for TRALI: patients who had hematologic malignancies and were undergoing induction chemotherapy and patients with cardiac disease requiring coronary artery bypass surgery.
In the present study, none of the cases represented these risk groups, and, thus, these factors could not be studied. The recipient risk factor with the strongest association with TRALI was spine surgery. Of the 6 patients with TRALI, 3 underwent spinal surgery. In these patients, surgery may have been the first hit (tissue trauma/inflammation) and transfusion the second hit that triggered the development of TRALI. In the study by Silliman et al, 6 anti-leukocyte-specific antibodies were found in only 3.6% of the TRALI cases, whereas all cases evaluated in our study revealed HLA-antibody concordance.
In this study, female sex of the donors did not seem to substantially increase the risk of TRALI. In the United Kingdom, female plasma has been diverted for manufacturing since 2003 in efforts to decrease the incidence of TRALI cases. Since the implementation of this practice, there has been a decrease in the number of TRALI cases in the United Kingdom. 17 Although there are published reports that HLA and granulocyte antibodies probably contribute to TRALI, it is evident that their presence is not sufficient to cause TRALI in all potentially susceptible patients. 14, 15 Although evidence supporting the implementation of preferential use of male donor plasma does not seem to be conclusive, the American Association of Blood Banks recommends that blood collecting facilities implement interventions to minimize preparation of high plasma-volume components from donors known to be leukocyte alloimmunized or at increased risk of leukocyte alloimmunization by November 2007. 18 One of the limitations of this pilot study is the small sample of cases during the course of 3 years at 1 institution. This resulted in wide CIs that do not permit firm conclusions about any other risk factors or whether whole blood confers more risk than every other type of blood product. Another limitation is the lack of availability of samples from blood products that were transfused into control subjects, which could be tested for biologic response modifiers. Recipient HLA expression and presence of HLA antibodies in donor plasma may be a risk factor for TRALI, but this was also not assessed owing to the lack of samples for control subjects. Such samples were not available because the residues from units used for recipients who do not have transfusion reactions are routinely discarded. It is difficult to interpret the laboratory results found for the TRALI cases alone because HLA and granulocyte antibody testing was not performed in any of the control subjects. Given the dependence on clinician reports of cases in this study, other cases of TRALI could have been missed.
A much larger prospective 5-year TRALI study is underway at our institution and the Mayo Clinic to determine the current incidence of TRALI and to identify recipient and donor risk factors associated with the syndrome. The design is a case-control (1:1 ratio) study stratified by volume of transfusion: low (1-2 U), medium (3-9 U), and high (≥10 U).
A computerized system electronically surveys arterial blood gases performed in transfusion recipients within 12 hours after blood is issued from the blood bank. Cases are recipients of blood products in whom new acute lung injury develops during or within 6 hours after transfusion as defined by the National Heart, Lung, and Blood Institute working group definition. 2 Control subjects are transfusion recipients in whom acute lung injury does not develop. Control subjects are stratified by volume of transfusion to reflect the TRALI cases identified. During the 5-year study period, 175 cases and 175 control subjects are anticipated to be enrolled at the University of California San Francisco and Mayo Clinic. One design element in the study is to reserve the residual samples from the units used for the control subjects, as well as those used for patients with TRALI to test for risk factors.
It is anticipated that large, prospective case-control studies will further delineate the important risk factors and pathogenesis for TRALI. In addition, if whole blood is confirmed as an important risk factor, understanding of the means by which it may contribute to the development of TRALI in an antibody-independent process should be investigated. Such knowledge would then aid in the prevention of TRALI and management of implicated donors.
